OpGen (OPGN) to Release Quarterly Earnings on Thursday

OpGen (NASDAQ:OPGNGet Rating) is set to announce its earnings results after the market closes on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

OpGen (NASDAQ:OPGNGet Rating) last issued its quarterly earnings data on Thursday, May 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. OpGen had a negative return on equity of 72.67% and a negative net margin of 680.36%. The company had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.05 million. On average, analysts expect OpGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OpGen Price Performance

Shares of OPGN opened at $0.59 on Thursday. OpGen has a 1 year low of $0.31 and a 1 year high of $3.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.76 and a quick ratio of 1.69. The company has a market capitalization of $27.24 million, a price-to-earnings ratio of -0.69 and a beta of -0.37. The business has a 50-day moving average of $0.55 and a 200-day moving average of $0.66.

Analyst Upgrades and Downgrades

OPGN has been the subject of a number of analyst reports. StockNews.com initiated coverage on OpGen in a research report on Thursday, July 28th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OpGen in a research report on Friday, June 10th. Finally, Alliance Global Partners downgraded OpGen to a “neutral” rating in a research report on Tuesday, July 19th.

OpGen Company Profile

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Earnings History for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.